Spyglass Pharma Inc 's ROE per quarter

Return on Equity, Quarterly Results, Trends, Rankings, Statistics

What is ROE for Spyglass Pharma Inc in the second quarter 2026?
Spyglass Pharma Inc had a negative return on equity (ROE) of -2566.15%, due to the net loss of $-2 billion, during the twelve months ending in the second quarter 2026.

Within the Diversified industry Spyglass Pharma Inc achieved the highest return on equity. While the total ranking for ROE unchanged, relative to the first quarter 2026 at no. .

What is ROE?

Select the Comparisons :

None ▼

Select the Ratio:

Return on Equity ROE▼

None ▼

Return on Equity ROE▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

Return On Equity	(Jun 30 2026) II. Quarter	(Mar 31 2026) I. Quarter	(Dec 31 2025) IV. Quarter	(Jun 30 2025) II. Quarter	(Mar 31 2025) I. Quarter
Y / Y Equity Change	-98.2 %	-97.92 %	-	-	-
Y / Y Net Income Change	-	-	-	-	-75.28 %
Net Income (TTM) in Millions	-2,073	-1,935	-1,406	1,296	2,110
Return On Equity (TTM)	-2566.15 %	-59.57 %	-22.7 %	14.52 %	18.23 %
SGP's Total Ranking	#	#	#	#	#
Equity (TTM) in Millions	232	250	-99	-60	12,900
Seq. Equity Change	-7.1 %	-	-	-	7.19 %
Seq. Net Income Change	-	-	-	-	-76.96 %

Back to SGP Management Effectiveness >> SGP's 5 Years Annual ROE >> Compare SGP ROE to its Competitors

Return On Equity Company Ranking
Within:	No.
Industry	#
Sector	#
Overall	#

Return On Equity Statistics
High	Average	Low
0 %	0 %	0 %

SGP Annual Return On Equity	(Dec 31 2025) 2025	(FY 2008) (Dec. 30, 2008)	(FY 2007) (Dec. 30, 2007)	(FY 2006) (Dec. 30, 2006)	(FY 2005) (Dec. 30, 2005)
Total Equity in Millions	-99	10,529	10,385	7,908	7,387
Y / Y Equity Change	-	1.39 %	31.32 %	7.05 %	-2.24 %
Net Income in Millions	-40	1,795	-1,473	1,121	269
Y / Y Net Income Change	-	-	-	316.73 %	-
Return On Equity	-	17.05 %	-14.18 %	14.18 %	3.64 %

Back to SGP Management Effectiveness >> SGP's 5 Years Annual ROE >> Compare SGP ROE to its Competitors

Annual Roe Comment

In 2025 ROE decreased compared to the previous year to 3.64 %, due to deterioration of net income.

More Return On Equity Ratios
Diversified Industry Roe Trends and Statistics
Consumer Non Cyclical Sector Return On Equity Statistics
SGP's' Return on Equity at Yahoo Finance
SGP's Roe Ratio versus Diversified Industry, Consumer Non Cyclical Sector and overall Market
Highest Ranking Return On Equity
Lowest Ranking Return On Equity
Subscribers only: Roe for SGP's Competitors
Subscribers only: Roe for Spyglass Pharma Inc 's Suppliers
Subscribers only: Return On Equity for SGP's Customers

Companies with similar Return On Equity at Jun 30 2026, within Consumer Non Cyclical Sector

ROE

Date modified: 2026-09-05T15:30:42+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.